Ignite Creation Date:
2025-12-24 @ 1:40 PM
Ignite Modification Date:
2025-12-29 @ 10:38 AM
Study NCT ID:
NCT06649695
Status:
RECRUITING
Last Update Posted:
2025-09-25
First Post:
2024-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Sponsor:
European Myeloma Network B.V.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-07-02
Start Date Type:
ACTUAL
Primary Completion Date:
2028-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-09
Completion Date Type:
ESTIMATED
First Submit Date:
2024-10-18
First Submit QC Date:
None
Study First Post Date:
2024-10-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-24
Last Update Post Date:
2025-09-25
Last Update Post Date Type:
ESTIMATED